Human Growth Hormone vs Sermorelin.

Human growth hormone (hGH, also called somatotropin) is a 191-amino-acid, single-chain polypeptide hormone secreted by somatotroph cells of the anterior pituitary gland. The pharmaceutical form used in medicine and research is recombinant human growth hormone (rhGH, generic name somatropin), an identical 22 kDa sequence manufactured in E. coli or mammalian cells. It is one of the most studied protein hormones, marketed under brands such as Genotropin, Norditropin, Humatrope, Saizen, Nutropin, and Omnitrope.

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary to release growth hormone (GH). This 1-29 fragment is the shortest portion of GHRH that retains full biological activity, so sermorelin behaves as a functional GHRH analog (a "secretagogue") rather than as growth hormone itself. It was marketed under the brand names Geref and Geref Diagnostic.

GH binds a single GH receptor (GHR) that dimerizes and signals through the JAK2/STAT5 pathway, driving transcription of target genes including IGF-1. Much of GH's anabolic and growth-promoting action is mediated indirectly by hepatic and local insulin-like growth factor 1 (IGF-1), while GH itself exerts direct effects that are often metabolically opposite to insulin: it stimulates lipolysis, promotes protein accretion, and induces a state of insulin resistance that raises blood glucose. Endogenous secretion is pulsatile, stimulated by hypothalamic GHRH and ghrelin and suppressed by somatostatin, with negative feedback from IGF-1 and GH itself. The net physiologic effects include longitudinal bone growth at open epiphyses, increased lean body mass, reduced fat mass, and altered glucose and lipid handling.

Sermorelin binds the GHRH receptor on pituitary somatotroph cells, a Gs-protein-coupled receptor, raising intracellular cAMP and stimulating synthesis and pulsatile secretion of endogenous growth hormone. Because it acts upstream on the pituitary rather than supplying exogenous GH, its effect is gated by an intact pituitary and remains subject to normal physiological brakes, most importantly negative feedback from somatostatin and from GH/IGF-1. Downstream, any GH released drives hepatic production of insulin-like growth factor 1 (IGF-1). This "releaser" mechanism is the basis for the long-standing claim that sermorelin produces a more physiologic, pulsatile GH profile than direct recombinant GH injection, though that pharmacodynamic difference has not been shown to translate into superior clinical outcomes.

The strongest human evidence is for replacement in diagnosed GH deficiency: recombinant somatropin is FDA-approved and supported by randomized trials and systematic reviews (e.g., Health Technology Assessment 2010, PMID 20849734, for pediatric growth disorders) showing improved growth velocity and adult height in children and improved body composition and quality of life in adult GHD (reviewed in Pituitary 2006, PMID 17077947). More recently, a long-acting analog, once-weekly somapacitan, was effective and well tolerated versus placebo and daily GH in adult GHD in a randomized phase 3 trial (J Clin Endocrinol Metab 2020, PMID 32022863). By contrast, evidence for GH in healthy older adults is weak and unfavorable: the landmark Rudman study (N Engl J Med 1990, PMID 2355952) reported body-composition changes in men over 60 but was small and uncontrolled for clinical endpoints, and a systematic review (Liu et al., Ann Intern Med 2007, PMID 17227934) concluded GH produces only small body-composition changes in the healthy elderly while increasing adverse events, and cannot be recommended as anti-aging therapy. Claims of fat loss, muscle gain, or longevity in healthy or athletic populations are not supported by robust controlled human outcome data.

The strongest human evidence is in pediatric diagnostics and idiopathic GH deficiency: sermorelin was studied and FDA-approved both as a provocative test of pituitary GH reserve and for treating growth failure in children with GHRH-responsive (hypothalamic) GH deficiency, where it can increase growth velocity (reviewed in BioDrugs 1999, PMID 18031173). Evidence for the popular adult "anti-aging," body-composition, sleep, and recovery claims is largely mechanistic or extrapolated rather than demonstrated; a frequently cited Clinical Interventions in Aging review (PMID 18046908) frames sermorelin in adult GH insufficiency as a rational but largely hypothetical approach, not an outcome-proven therapy. Notably, the well-known randomized controlled trial showing cognitive benefit from a GHRH analog in older adults and mild cognitive impairment (Baker et al., Archives of Neurology 2012, PMID 22869065) used tesamorelin, a different stabilized GHRH(1-44) analog, not sermorelin, so it should not be cited as direct sermorelin evidence. Overall, robust randomized trials of sermorelin for adult quality-of-life, longevity, or athletic outcomes are essentially absent.

Documented adverse effects, drawn largely from the healthy-elderly trials and GHD populations, include fluid retention and edema, arthralgias and joint swelling, carpal tunnel syndrome, and impaired glucose tolerance or new-onset diabetes due to GH-induced insulin resistance (Liu 2007, PMID 17227934). Acromegaly-like features and gigantism follow chronic GH excess. Long-term safety signals exist: the French SAGhE analysis and related cohorts raised concern about excess circulatory/cerebrovascular mortality after childhood GH treatment, prompting an FDA safety review, though the larger pooled SAGhE cohort (Lancet Diabetes Endocrinol 2020) provided more reassuring overall mortality data; the question of long-term cardiovascular and neoplastic risk remains incompletely resolved. GH is contraindicated in active malignancy, acute critical illness, and proliferative diabetic retinopathy. Non-prescription "GH" products and gray-market vials carry additional risks of misidentification, contamination, and incorrect labeling that are not characterized in any controlled study.

In its approved pediatric and diagnostic use, sermorelin was generally well tolerated, with the most common reactions being transient injection-site reactions (redness, swelling, pain) and, less often, flushing, headache, dizziness, or transient warmth; uncommon hypersensitivity reactions were reported. Because it raises GH and IGF-1, the theoretical class concerns that apply to GH-axis stimulation are relevant, including fluid retention, joint or muscle discomfort, insulin resistance/glucose changes, and the general caution around GH-axis stimulation in people with active malignancy. Most safety data come from short-term, monitored, mostly pediatric settings; long-term safety of chronic adult use, especially via compounded products sold for off-label "wellness" purposes, has not been established, and compounded preparations carry additional uncertainty around purity, sterility, and dose accuracy. No doses or regimens are provided here.

Recombinant somatropin is FDA-approved (first approved 1985–1987) for specific indications including pediatric GH deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature, idiopathic short stature, chronic renal insufficiency, adult GH deficiency, and HIV-associated wasting; non-approved uses such as anti-aging, bodybuilding, or athletic enhancement are off-label and, in the US, distribution for such uses is specifically restricted by law. GH is a prohibited substance in and out of competition under the World Anti-Doping Agency (WADA) code.

Sermorelin acetate was FDA-approved (brand Geref / Geref Diagnostic) for diagnostic testing of pituitary GH reserve and for idiopathic GH deficiency in children, but the branded products were voluntarily withdrawn from the US market in 2008 for commercial reasons (not for safety or efficacy failures); it is currently available in the US only as a compounded preparation, with no FDA-approved finished-drug product on the market.